AGI-1067 [succinobucol] as a novel antidiabetic agent evaluation study

Next Previous
Trial Profile

AGI-1067 [succinobucol] as a novel antidiabetic agent evaluation study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2010

At a glance

  • Drugs Succinobucol (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ANDES
  • Sponsors AtheroGenics

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Aug 2008 Primary endpoint achieved, as reported in a AtherGenics media release.
    • 04 Jun 2008 Final results are expected in the third quarter of 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top